The aims of the Tissue Banking and Molecular Assessment Core are to:1. Receive, process, store, and retrieve samples from children and adults with acute lymphoblastic leukemiaand appropriately distribute material to the scientific and clinical projects within the Program.2. Perform real time quantitative polymerase chain reaction assays using as markers the unique IgH and TCRrearrangements identified in the diagnostic patient samples.Core C will work to obtain peripheral blood and bone marrow samples,isolate the mononuclear cell fraction and cryopreserve cells, RNA and DNA from tumor samples. The Corewill distribute these samples to the Projects as required and will prioritize the use of samples in which cellnumbers are limiting. This will allow for distribution of the most appropriate samples to each Project toachieve the scientific aims of Projects 1, Project 3, Project 4, Project 5, and Project 6. The Core willprovide molecular biologic analysis of immunoglobulin heavy chain (IgH) and T cell receptor (TCR) generearrangements in diagnostic samples and perform quantitative polymerase chain reaction assays in posttreatment samples using as markers these patient specific gene rearrangements. The goal is to assess thedynamics of the eradication of minimal residual disease and identify patients at sufficiently high risk of relapseto be candidates for experimental treatment approaches in Project 6, using the targets identified withinProjects 1, 3, 4 and 5. The Core is essential to achieve the full translational potential of this Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA068484-11A1
Application #
7058466
Study Section
Subcommittee G - Education (NCI)
Project Start
2005-12-01
Project End
2010-11-30
Budget Start
2005-12-01
Budget End
2007-04-30
Support Year
11
Fiscal Year
2006
Total Cost
$213,351
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bansal, Neha; Barach, Paul; Amdani, Shahnawaz M et al. (2018) When is early septal myectomy in children with hypertrophic cardiomyopathy justified? Transl Pediatr 7:362-366
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945
Lipshultz, Steven E (2018) Letter by Lipshultz Regarding Article, ""Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"" Circ Res 122:e62-e63
Temple, Jennifer L; Bernard, Christophe; Lipshultz, Steven E et al. (2017) The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry 8:80
Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226
Hutchins, Kelley K; Siddeek, Hani; Franco, Vivian I et al. (2017) Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol 83:455-465
Fraser, Raphael André; Lipsitz, Stuart R; Sinha, Debajyoti et al. (2016) Approximate median regression for complex survey data with skewed response. Biometrics 72:1336-1347
Lipshultz, Steven E; Anderson, Lynn M; Miller, Tracie L et al. (2016) Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer 122:946-53
Bona, Kira; Blonquist, Traci M; Neuberg, Donna S et al. (2016) Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). Pediatr Blood Cancer 63:1012-8
Seftel, Matthew D; Neuberg, Donna; Zhang, Mei-Jie et al. (2016) Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol 91:322-9

Showing the most recent 10 out of 214 publications